) to discuss its fiscal 2011 second quarter financial results. Cipher invites all interested parties to participate. You can join the call by dialing 647-427-7450 or 1-888-231-8191 . Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.
Larry Andrews , President and CEO, will chair the call. A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions. A taped replay of the conference call will be available until Tuesday, August 2, 2011 by calling 416-849-0833 or 1-800-642-1687, reference number 76894481.
A live audio webcast of the conference call will be available throughwww.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. An archived replay of the webcast will be available for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. Cipher's second product, an extended-release version of the pain reliever tramadol, has received final FDA approval and is expected to be launched by Vertical Pharmaceuticals in the United States in Q3 2011. The Company's third product, a novel formulation of the acne treatment isotretinoin, recently completed its final Phase III safety study.
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visitwww.cipherpharma.com.
For further information:
No comments:
Post a Comment